-
-
-
-
-
-
-
AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041
-
-
-
-
-
-
-
AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function
-
-
-
-
-
-
-
AB Science shares initial phase 1 data for AB8939-venetoclax combination
-
-
-
-
-
-
-
AllianceBernstein reports August assets under management at $844 billion
-
-
-
-
-
-
-
AB Science receives European approvals for phase 3 ALS study
-
-
-
-
-
-
-
AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036
-
-
-
-
-
-
-
AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual Meeting
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

